Last reviewed · How we verify
NCT05367648
Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects
NA trial testing Elio in Muscle Injury in 2 participants. Completed in 24 November 2020.
9 October 2020
Quick facts
| Lead sponsor | Nuritas Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 2 |
| Start date | 24 September 2020 |
| Primary completion | 9 October 2020 |
| Estimated completion | 24 November 2020 |
| Sites | 1 location across Ireland |
Drugs / interventions tested
- Elio
- Placebo
Conditions studied
- Muscle Injury — all drugs for Muscle Injury →
Sponsor
Nuritas Ltd
Who can join
Adults 30 to 45, male only, with Muscle Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The effect of exercise on serum concentrations of creatine kinase (CK) and subsequent use of protein hydrolysate supplementation, Elio, to influence the expression of CK following resistance type exercise in male subjects. A two subject trial of Elio administered 3 grams per day in assessing its effects on post-exercise increases in markers associated with muscle injury and exertion
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05367648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Elio
Trials testing the same drug.
- NCT05159375 — Effects of Protein Hydrolysate Supplementation Influencing Strength Recovery and Expression of Muscle Damage Markers Pos · NA · completed
Other recruiting trials for Muscle Injury
Currently open trials in the same condition.
- NCT05746650 — Improving Tissue Repair After Injury in the Muscle-tendon Interface Muscle Tissue Injury · NA · recruiting
- NCT05344183 — Immediate and Short-term Effects of Low-level Laser · NA · active not recruiting
- NCT03660969 — Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease · active not recruiting
Other Nuritas Ltd trials
Trials by the same sponsor.
- NCT07528469 — The Effects of PeptiStrong and Whey on Muscle Function In Older Adults · NA · not yet recruiting
- NCT07258433 — Effects of PeptiSleep on Sleep Quality in Healthy Adults · NA · recruiting
- NCT07322653 — The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population · NA · recruiting
- NCT06894875 — Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance · NA · recruiting
- NCT06440213 — A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05367648 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nuritas Ltd
- Last refreshed: 10 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing